Dianthus Therapeutics Inc
NASDAQ:DNTH
Dianthus Therapeutics Inc
NASDAQ:DNTH
Price:
61.45
USD
10.94%
Market Closed
Market Cap:
$2.6B
Relative Value
The Relative Value of one
DNTH
stock under the Base Case scenario is
0.33
USD.
Compared to the current market price of 61.45 USD,
Dianthus Therapeutics Inc
is
Overvalued by 99%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DNTH
Relative Value
Base Case
0.33
USD
Overvaluation 99%
Multiples Across Competitors
DNTH Competitors Multiples
Dianthus Therapeutics Inc Competitors
Dianthus Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Dianthus Therapeutics Inc
NASDAQ:DNTH
|
2.7B USD | 863.7 | -21 | -16.1 | -16.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
417.5B USD | 6.8 | 99.9 | 16.3 | 22.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.7B USD | 5.6 | 26.5 | 15.2 | 15.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.3B USD | 6.3 | 21.7 | 13.5 | 16.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.5B USD | 10.1 | 30.7 | 23.2 | 24.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.1B USD | 5.8 | 18.5 | 13.9 | 15.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.1B AUD | 3.2 | 35.7 | 11.7 | 14.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.3B EUR | 11.2 | 35.8 | 39 | 39.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
